ERBB2 and neoplasm: Therefore, in view of the original threshold was set for trastuzumab treatment [7, 8] but not for the other anti-HER2 treatments or their combination, it is likely that HER2-low tumours may benefit from other FDA approved anti-HER2 treatments in addition to trastuzumab deruxtecan.